Trial Profile
Evaluation of [18F] florbetaben in subjects participating in the Parkinson's Progression Markers Initiative (PPMI) Protocol
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Parkinson's disease
- Focus Biomarker; Diagnostic use; Pharmacodynamics
- Acronyms PPMI
- 08 Jun 2017 Results of longitudinal analysis of PRECEPT and PPMI trials to estimate the degree of enrichment and impact of reduced dopamine transporter (DAT) binding as a biomarker on future trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 28 Apr 2016 New trial record